Get the Stockscreener App
2.36
0.43%
0.010
After Hours:
2.36
Neurobo Pharmaceuticals Inc stock is traded at $2.36, with a volume of 13,013.
It is up +0.43% in the last 24 hours and down -15.11% over the past month.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
See More
Previous Close:
$2.35
Open:
$2.35
24h Volume:
13,013
Relative Volume:
0.30
Market Cap:
$20.35M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.2659
EPS:
-8.877
Net Cash Flow:
$-10.85M
1W Performance:
-1.67%
1M Performance:
-15.11%
6M Performance:
-42.86%
1Y Performance:
+458.71%
1-Day Range:
$2.32
$2.44
1-Week Range:
$2.30
$2.54
52-Week Range:
$0.38
$6.7499
Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile
Name
Neurobo Pharmaceuticals Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE, MA
Compare NRBO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRBO
Neurobo Pharmaceuticals Inc
|
2.36 | 20.35M | 0 | -12.47M | -10.85M | -8.877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
Neurobo Pharmaceuticals Inc Stock (NRBO) Latest News
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA By Investing.com - Investing.com Canada
NeuroBo Pharmaceuticals announces relignment, change name - TipRanks
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA - Investing.com
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes - TipRanks
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires Shares in NeuroBo Pharmaceuticals Inc - GuruFocus.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 - Smartkarma
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - cnhinews.com
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation - Simply Wall St
NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research
NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa
NeuroBo reports positive early trial results for obesity drug - Investing.com
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance
NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency
Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat
Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance
BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com
Lombard Odier Asset Management Europe Ltd Reduces Stock Position in nVent Electric plc (NYSE:NVT) - Defense World
Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Increases Dividend to $0.81 Per Share - MarketBeat
Amalgamated Bank Reduces Holdings in nVent Electric plc (NYSE:NVT) - Defense World
Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com
BMO sustains stock target, outperform on Novo Nordisk amid trial results - Investing.com India
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results - Investopedia
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Yahoo Finance
Novo Nordisk Shares Slide After Disappointing Obesity Pill Trial - Finimize
Novo Nordisk shares drop more than 4% on disappointing obesity pill data - The Economic Times
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear? - Yahoo Finance
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update - StreetInsider.com
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data - Yahoo Finance
Novo Shares Fall on Safety Data for New Weight-Loss Drug - BNN Bloomberg
Novo drops to 1-month low after Monlunabant trial data - XM
NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Australia
NeuroBo shareholders approve significant stock issuance - Investing.com India
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential (NYSE:NVO) - Seeking Alpha
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Clinical Trials Arena
Neurobo Pharmaceuticals Inc Stock (NRBO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):